173 related articles for article (PubMed ID: 32650066)
1. In silico drug repositioning of FDA-approved drugs to predict new inhibitors for alpha-synuclein aggregation.
Jafaripour SS; Gharaghani S; Nazarshodeh E; Haider S; Saboury AA
Comput Biol Chem; 2020 Oct; 88():107308. PubMed ID: 32650066
[TBL] [Abstract][Full Text] [Related]
2. Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease.
Vittorio S; Adornato I; Gitto R; Peña-Díaz S; Ventura S; De Luca L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1727-1735. PubMed ID: 32924648
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore modeling and 3D-QSAR study for the design of novel α-synuclein aggregation inhibitors.
Yang J; Hu J; Zhang G; Qin L; Wen H; Tang Y
J Mol Model; 2021 Aug; 27(9):260. PubMed ID: 34432157
[TBL] [Abstract][Full Text] [Related]
4. Deciphering the anti-Parkinson's activity of sulphated polysaccharides from Chlamydomonas reinhardtii on the α-Synuclein mutants A30P, A53T, E46K, E57K and E35K.
Panigrahi GP; Rane AR; Vavilala SL; Choudhary S
J Biochem; 2019 Dec; 166(6):463-474. PubMed ID: 31385584
[TBL] [Abstract][Full Text] [Related]
5. Complex of EGCG with Cu(II) Suppresses Amyloid Aggregation and Cu(II)-Induced Cytotoxicity of α-Synuclein.
Teng Y; Zhao J; Ding L; Ding Y; Zhou P
Molecules; 2019 Aug; 24(16):. PubMed ID: 31416122
[TBL] [Abstract][Full Text] [Related]
6. C9-Functionalized Doxycycline Analogs as Drug Candidates to Prevent Pathological α-Synuclein Aggregation and Neuroinflammation in Parkinson's Disease Degeneration.
Rose C; Tomas-Grau RH; Zabala B; Michel PP; Brunel JM; Chehín R; Raisman-Vozari R; Ferrié L; Figadère B
ChemMedChem; 2024 Jun; 19(12):e202300597. PubMed ID: 38526011
[TBL] [Abstract][Full Text] [Related]
7. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
[TBL] [Abstract][Full Text] [Related]
8. Discovery of styrylaniline derivatives as novel alpha-synuclein aggregates ligands.
Bian J; Liu YQ; He J; Lin X; Qiu CY; Yu WB; Shen Y; Zhu ZY; Ye DY; Wang J; Chu Y
Eur J Med Chem; 2021 Dec; 226():113887. PubMed ID: 34624824
[TBL] [Abstract][Full Text] [Related]
9. Two-step screening method to identify α-synuclein aggregation inhibitors for Parkinson's disease.
Hideshima M; Kimura Y; Aguirre C; Kakuda K; Takeuchi T; Choong CJ; Doi J; Nabekura K; Yamaguchi K; Nakajima K; Baba K; Nagano S; Goto Y; Nagai Y; Mochizuki H; Ikenaka K
Sci Rep; 2022 Jan; 12(1):351. PubMed ID: 35013421
[TBL] [Abstract][Full Text] [Related]
10. Scutellarin inhibits the uninduced and metal-induced aggregation of α-Synuclein and disaggregates preformed fibrils: implications for Parkinson's disease.
Zaidi FK; Deep S
Biochem J; 2020 Feb; 477(3):645-670. PubMed ID: 31939603
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects.
AlNajjar YT; Gabr M; ElHady AK; Salah M; Wilms G; Abadi AH; Becker W; Abdel-Halim M; Engel M
Eur J Med Chem; 2022 Jan; 227():113911. PubMed ID: 34710745
[TBL] [Abstract][Full Text] [Related]
12. A Self-Assembled α-Synuclein Nanoscavenger for Parkinson's Disease.
Liu J; Liu C; Zhang J; Zhang Y; Liu K; Song JX; Sreenivasmurthy SG; Wang Z; Shi Y; Chu C; Zhang Y; Wu C; Deng X; Liu X; Song J; Zhuang R; Huang S; Zhang P; Li M; Wen L; Zhang YW; Liu G
ACS Nano; 2020 Feb; 14(2):1533-1549. PubMed ID: 32027482
[TBL] [Abstract][Full Text] [Related]
13. Artificial intelligence-driven drug repositioning uncovers efavirenz as a modulator of α-synuclein propagation: Implications in Parkinson's disease.
Kim JB; Kim SJ; So M; Kim DK; Noh HR; Kim BJ; Choi YR; Kim D; Koo H; Kim T; Woo HG; Park SM
Biomed Pharmacother; 2024 May; 174():116442. PubMed ID: 38513596
[TBL] [Abstract][Full Text] [Related]
14. Identification of Bile Acid-Derived Chemical Chaperone(s) Targeting E46K-Mutated Alpha-Synuclein Protein to Treat Parkinson's Disease: Molecular Modelling, Docking, ADME, and Simulation Studies.
Kaur N; Singh R; Das AP; Agarwal SM; Dhingra N; Kaur T
Appl Biochem Biotechnol; 2024 Apr; 196(4):2086-2109. PubMed ID: 37466885
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic Oligomers and Fibrils Trapped in a Gel-like State of α-Synuclein Assemblies.
Kumar R; Das S; Mohite GM; Rout SK; Halder S; Jha NN; Ray S; Mehra S; Agarwal V; Maji SK
Angew Chem Int Ed Engl; 2018 May; 57(19):5262-5266. PubMed ID: 29524323
[TBL] [Abstract][Full Text] [Related]
16. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
Sharma N; Rao SP; Kalivendi SV
Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
[TBL] [Abstract][Full Text] [Related]
17. In vitro inhibition of α-Synuclein aggregation and disaggregation of preformed fibers by polyphenol hybrids with 2-conjugated benzothiazole.
Zhao YD; Zhang W; Xing LZ; Xu J; Shi WM; Zhang YX
Bioorg Med Chem Lett; 2024 Jun; 105():129752. PubMed ID: 38631541
[TBL] [Abstract][Full Text] [Related]
18. α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.
Singh SK; Dutta A; Modi G
Future Med Chem; 2017 Jun; 9(10):1039-1053. PubMed ID: 28632413
[TBL] [Abstract][Full Text] [Related]
19. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
20. Comparison of α-Synuclein Fibril Inhibition by Four Different Amyloid Inhibitors.
Jha NN; Kumar R; Panigrahi R; Navalkar A; Ghosh D; Sahay S; Mondal M; Kumar A; Maji SK
ACS Chem Neurosci; 2017 Dec; 8(12):2722-2733. PubMed ID: 28872299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
